Ariad updates investors on portfolio
USA-based Ariad Pharmaceuticals has updated investors on its 2009 key corporate objectives and financial guidance. The two primary drivers of the deforolimus opportunity are completion of the SUCCEED Phase III trial of the compound in patients with metastatic sarcomas and completion of the Phase II studies of deforolimus in patients with other types of solid tumors. The SUCCEED trial is on track for full patient accrual in fourth-quarter 2009. Additionally, the first and second interim efficacy analyses of the study are expected to take place this year, with their exact timing based on the occurrence of a pre-specified number of clinical events. The company expects to begin filing the initial portions of the New Drug Application for the drug by next year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze